Phase I/II Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 30 May 2018
Price : $35 *
At a glance
- Drugs Bortezomib (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 23 May 2018 Status changed from active, no longer recruiting to completed.
- 14 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
- 14 Nov 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2018.